Gene expression and silencing for improved islet transplantation

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Islet transplantation has great potential as an effective means of treating type 1 diabetes. However, its successful application greatly depends on the rapid revascularization of islets and prevention from their apoptotic cell death. We co-expressed human vascular endothelial growth factor (hVEGF) and human interleukin-1 receptor antagonist (hIL-1Ra) after transduction of human islets with Adv-hVEGF-hIL-1Ra. Since hepatocyte growth factor (HGF) increases β-cell proliferation and promotes revascularization of islets, we also constructed Adv-hHGF-hIL-1Ra. There was dose and time dependent expression of hVEGF and hIL-1Ra or hHGF and hIL-1Ra by islets, which led to decrease in caspase-3 activity and apoptosis induced by a cocktail of TNF-α, IL-1β and IFN-γ. Compared to non-treated islets, transduction of islets with these bipartite Adv vectors prior to transplantation under the kidney capsules of diabetic NOD-SCID mice reduced the blood glucose levels, and increased serum insulin and c-peptide levels. Immunohistochemical staining of the islet bearing kidney sections was positive for human insulin, growth factor (hVEGF or hHGF) and von Willebrand factor. Transduction with Adv-caspase-3-shRNA also prevented islets from cytokine induced apoptosis and improved islet transplantation. In conclusion, bipartite Adv vector efficiently co-expressed both growth factor and antiapoptotic genes or shRNA targeting pro-apoptotic genes, decreases apoptosis and improves the outcome of islet transplantation.

Original languageEnglish (US)
Pages (from-to)262-267
Number of pages6
JournalJournal of Controlled Release
Volume140
Issue number3
DOIs
StatePublished - Dec 16 2009

Fingerprint

Islets of Langerhans Transplantation
Gene Silencing
Interleukin-1 Receptors
Gene Expression
Apoptosis
Caspase 3
Small Interfering RNA
Intercellular Signaling Peptides and Proteins
Insulin
Inbred NOD Mouse
Hepatocyte Growth Factor
SCID Mice
von Willebrand Factor
Type 1 Diabetes Mellitus
Interleukin-1
Kidney Transplantation
Genes
Capsules
Blood Glucose
Cell Death

Keywords

  • Adenoviral vectors
  • Caspase-3
  • Hepatocyte growth factor
  • Human islets
  • IL-1Ra
  • Islet transplantation
  • hVEGF
  • siRNA

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Gene expression and silencing for improved islet transplantation. / Mahato, Ram I.

In: Journal of Controlled Release, Vol. 140, No. 3, 16.12.2009, p. 262-267.

Research output: Contribution to journalArticle

@article{3f2b8043ad3c4041962e481260f71909,
title = "Gene expression and silencing for improved islet transplantation",
abstract = "Islet transplantation has great potential as an effective means of treating type 1 diabetes. However, its successful application greatly depends on the rapid revascularization of islets and prevention from their apoptotic cell death. We co-expressed human vascular endothelial growth factor (hVEGF) and human interleukin-1 receptor antagonist (hIL-1Ra) after transduction of human islets with Adv-hVEGF-hIL-1Ra. Since hepatocyte growth factor (HGF) increases β-cell proliferation and promotes revascularization of islets, we also constructed Adv-hHGF-hIL-1Ra. There was dose and time dependent expression of hVEGF and hIL-1Ra or hHGF and hIL-1Ra by islets, which led to decrease in caspase-3 activity and apoptosis induced by a cocktail of TNF-α, IL-1β and IFN-γ. Compared to non-treated islets, transduction of islets with these bipartite Adv vectors prior to transplantation under the kidney capsules of diabetic NOD-SCID mice reduced the blood glucose levels, and increased serum insulin and c-peptide levels. Immunohistochemical staining of the islet bearing kidney sections was positive for human insulin, growth factor (hVEGF or hHGF) and von Willebrand factor. Transduction with Adv-caspase-3-shRNA also prevented islets from cytokine induced apoptosis and improved islet transplantation. In conclusion, bipartite Adv vector efficiently co-expressed both growth factor and antiapoptotic genes or shRNA targeting pro-apoptotic genes, decreases apoptosis and improves the outcome of islet transplantation.",
keywords = "Adenoviral vectors, Caspase-3, Hepatocyte growth factor, Human islets, IL-1Ra, Islet transplantation, hVEGF, siRNA",
author = "Mahato, {Ram I}",
year = "2009",
month = "12",
day = "16",
doi = "10.1016/j.jconrel.2009.04.011",
language = "English (US)",
volume = "140",
pages = "262--267",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Gene expression and silencing for improved islet transplantation

AU - Mahato, Ram I

PY - 2009/12/16

Y1 - 2009/12/16

N2 - Islet transplantation has great potential as an effective means of treating type 1 diabetes. However, its successful application greatly depends on the rapid revascularization of islets and prevention from their apoptotic cell death. We co-expressed human vascular endothelial growth factor (hVEGF) and human interleukin-1 receptor antagonist (hIL-1Ra) after transduction of human islets with Adv-hVEGF-hIL-1Ra. Since hepatocyte growth factor (HGF) increases β-cell proliferation and promotes revascularization of islets, we also constructed Adv-hHGF-hIL-1Ra. There was dose and time dependent expression of hVEGF and hIL-1Ra or hHGF and hIL-1Ra by islets, which led to decrease in caspase-3 activity and apoptosis induced by a cocktail of TNF-α, IL-1β and IFN-γ. Compared to non-treated islets, transduction of islets with these bipartite Adv vectors prior to transplantation under the kidney capsules of diabetic NOD-SCID mice reduced the blood glucose levels, and increased serum insulin and c-peptide levels. Immunohistochemical staining of the islet bearing kidney sections was positive for human insulin, growth factor (hVEGF or hHGF) and von Willebrand factor. Transduction with Adv-caspase-3-shRNA also prevented islets from cytokine induced apoptosis and improved islet transplantation. In conclusion, bipartite Adv vector efficiently co-expressed both growth factor and antiapoptotic genes or shRNA targeting pro-apoptotic genes, decreases apoptosis and improves the outcome of islet transplantation.

AB - Islet transplantation has great potential as an effective means of treating type 1 diabetes. However, its successful application greatly depends on the rapid revascularization of islets and prevention from their apoptotic cell death. We co-expressed human vascular endothelial growth factor (hVEGF) and human interleukin-1 receptor antagonist (hIL-1Ra) after transduction of human islets with Adv-hVEGF-hIL-1Ra. Since hepatocyte growth factor (HGF) increases β-cell proliferation and promotes revascularization of islets, we also constructed Adv-hHGF-hIL-1Ra. There was dose and time dependent expression of hVEGF and hIL-1Ra or hHGF and hIL-1Ra by islets, which led to decrease in caspase-3 activity and apoptosis induced by a cocktail of TNF-α, IL-1β and IFN-γ. Compared to non-treated islets, transduction of islets with these bipartite Adv vectors prior to transplantation under the kidney capsules of diabetic NOD-SCID mice reduced the blood glucose levels, and increased serum insulin and c-peptide levels. Immunohistochemical staining of the islet bearing kidney sections was positive for human insulin, growth factor (hVEGF or hHGF) and von Willebrand factor. Transduction with Adv-caspase-3-shRNA also prevented islets from cytokine induced apoptosis and improved islet transplantation. In conclusion, bipartite Adv vector efficiently co-expressed both growth factor and antiapoptotic genes or shRNA targeting pro-apoptotic genes, decreases apoptosis and improves the outcome of islet transplantation.

KW - Adenoviral vectors

KW - Caspase-3

KW - Hepatocyte growth factor

KW - Human islets

KW - IL-1Ra

KW - Islet transplantation

KW - hVEGF

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=70449704916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449704916&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2009.04.011

DO - 10.1016/j.jconrel.2009.04.011

M3 - Article

VL - 140

SP - 262

EP - 267

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -